Ab­b­Vie sweeps back-to-back PhI­I­Is for uter­ine fi­broid pa­tients, adding to elagolix's block­buster rep

Ab­b­Vie is on a roll.

The phar­ma gi­ant $AB­BV has rolled up its sec­ond and fi­nal pos­i­tive Phase III for elagolix, one of its top block­buster hope­fuls that is now be­ing point­ed to the FDA in search of a near-term ap­proval for treat­ing uter­ine fi­broids. And it’s al­ready in line for an ac­cel­er­at­ed thumbs up for en­dometrio­sis.

This sec­ond study fo­cused in on pa­tients suf­fer­ing from heavy men­stru­al bleed­ing. Re­searchers tracked a 76.2% clin­i­cal re­sponse rate in the drug arm, matched by on­ly 10% of the place­bo group.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER